| 1 |
Development of osteoarthritis drug with a novel mechanism of inflammasome blockade |
| Small Molecules |
Osteoarthritis |
Caspase |
Preclinical |
Innovo Therapeutics, Inc. |
RS-2023-00282719 |
|
| 2 |
Pre-clinical studies of DMOAD candidate DRT-101 for Osteoarthritis |
| Others |
Degenerative arthritis |
bmp7 |
Preclinical |
Darnatein |
RS-2023-00258278 |
|
| 3 |
Development of EFL.1101, a topical anticholinergic agent, for the Treatment of Hyperhidrosis |
| Small Molecules |
Hyperhidrosis |
Muscarinic M3 |
Preclinical |
eFlask |
RS-2023-00258121 |
|
| 4 |
Pre-clinical study and IND application of PAT101, a tophaceous gout treatment, using SelecAllTM technology |
| Recombinant Protein |
Gout |
Uric Acid |
Preclinical |
ProAbTech |
RS-2023-00219125 |
|
| 5 |
Development of Immunoferritin Cellem001 with Dual Immune Checkpoints Blockade and T/NK-tumor Cell Engager |
| Recombinant Protein |
NSCLC, Melanoma |
PD-L1, TIGIT |
Preclinical |
Cellemedy |
RS-2023-00218402 |
|
| 6 |
A novel GFRA1 agonist, JW0061 development for androgenic alopecia treatment |
| Small Molecules |
Androgenetic alopecia |
GFRA1 |
Preclinical |
JW Pharmaceutical |
RS-2023-00217372 |
|
| 7 |
Multi-modal cell-penetrating peptide for diabetic foot ulcer |
| Peptide |
Diabetic foot ulcer |
pre-let7 miRNA |
Preclinical |
StemMeditech Inc. |
RS-2022-00165887 |
|
| 8 |
Nonclinical Drug Development of anti-achondroplasia therapy for activated FGFR3 inhibition with NPR-B-Targeting Peptide |
| Peptide |
Achondroplasia |
NPR-B |
Preclinical |
Peptron, Inc |
HN21C1247 |
|
